The Impact of Weight-Loss Drugs on Healthcare and Obesity

Novo Nordisk and Eli Lilly are set to dominate the weight-loss drug market in the next couple of years with their drugs Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs have shown significant efficacy in reducing weight, with weight loss percentages reaching the mid-teens and even close to 20%. The obesity drug market is currently at a low penetration rate of around 2%, leaving ample room for growth. While more competition is expected in the future, Novo and Lilly have a first-mover advantage and are likely to maintain their dominance in the near term. The longer-term benefits of these drugs are expected to make it harder for payers to push back against covering the costs.